Idioma:

Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75

Becker, Allan ; Swern, Arlene ; Tozzi, Carol A. ; Yu, Qinfen ; Reiss, Theodore ; Knorr, Barbara

Current medical research and opinion, 2004-10, Vol.20 (10), p.1651-1659 [Periódico revisado por pares]

England: Informa UK Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75
Autor: Becker, Allan ; Swern, Arlene ; Tozzi, Carol A. ; Yu, Qinfen ; Reiss, Theodore ; Knorr, Barbara
Assuntos: Acetates - pharmacology ; Acetates - therapeutic use ; Adolescent ; Anti-Asthmatic Agents - pharmacology ; Anti-Asthmatic Agents - therapeutic use ; Asthma - complications ; Asthma - drug therapy ; Asthma - pathology ; Asthma, pediatric ; Child ; Double-Blind Method ; Efficacy ; Female ; FEV1 ; Forced Expiratory Volume - drug effects ; Humans ; Leukotriene receptor antagonist ; Male ; Placebos ; Quality of life ; Quinolines - pharmacology ; Quinolines - therapeutic use ; Severity of Illness Index ; Treatment Outcome
É parte de: Current medical research and opinion, 2004-10, Vol.20 (10), p.1651-1659
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
Descrição: SUMMARY Objectives: Montelukast is a potent leukotriene receptor antagonist effective for treating asthma symptoms in adult and pediatric patients. The purpose of this analysis was to assess the clinical efficacy of montelukast, a potent leukotriene-receptor antagonist, in a subgroup analysis of patients aged 6 years-14 years with milder asthma, defined as a percentage predicted forced expiratory volume in 1 s (FEV1) > 75% using data from a clinical trial of pediatric patients with a broad range of asthma severities. Research design and methods: The original previously published clinical trial was an 8-week multi-center, randomized, double-blind, parallel-group study conducted in 47 centers in the United States and Canada. The study compared the efficacy of once daily montelukast 5 mg to placebo in patients 6 years-14 years old with persistent asthma and an FEV1 ranging from 50% to 85% of predicted. A total of 87 patients in the montelukast group and 51 patients in the placebo group were selected from the original cohort of 336 patients based on percentage predicted FEV1 of > 75%. The primary endpoint was percentage change in FEV1 from baseline compared with placebo over 8 weeks of active treatment. Results: Montelukast significantly improved the primary endpoint of percentage change in FEV1 compared with placebo ( p = 0.005). Other efficacy endpoints were significantly improved on montelukast similar to efficacy in the original study. Conclusion: Montelukast significantly improved FEV1, clinic measured peak expiratory flow (PEF), reduced nocturnal awakenings, and improved quality of life in children with milder persistent asthma defined as an FEV1 > 75% of predicted.
Editor: England: Informa UK Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75

Becker, Allan ; Swern, Arlene ; Tozzi, Carol A. ; Yu, Qinfen ; Reiss, Theodore ; Knorr, Barbara

England: Informa UK Ltd

Buscando em bases de dados remotas. Favor aguardar.